[Form 4] Zevra Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Zevra Therapeutics director John B. Bode acquired 5,000 shares of the company's common stock on 08/19/2025 at a reported price of $9.165 per share. After the purchase he beneficially owns 45,000 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/20/2025.

Positive

• Director purchase disclosed: 5,000 shares acquired, showing insider transaction transparency
• Complete reporting details: transaction date, price ($9.165), and post-transaction ownership (45,000) provided

Negative

• None.

Insights

Financial Analyst

TL;DR Insider purchase of 5,000 shares by a director; transaction size is modest relative to typical market-moving insider trades.

The Form 4 documents a non-derivative purchase of 5,000 common shares at $9.165 on 08/19/2025, bringing the reporting person's holdings to 45,000 shares. This is a straightforward Section 16 disclosure without additional compensation, option exercises, or derivative activity. The filing indicates a single reporting person and was executed via attorney-in-fact.

Corporate Governance Expert

TL;DR Director-level purchase disclosed promptly; procedural filing appears complete and compliant with Section 16 reporting.

The report identifies John B. Bode as a director and shows a direct acquisition (code P). The Form 4 includes required details: transaction date, price, post-transaction beneficial ownership, and a signature by an attorney-in-fact. No amendments or derivative transactions are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bode John B

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		P		5,000	A	$9.165	45,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ZVRA director John B. Bode report on Form 4?

He reported a purchase of 5,000 common shares on 08/19/2025 at a price of $9.165, resulting in 45,000 shares beneficially owned.

When was the insider transaction for ZVRA executed and filed?

Executed on 08/19/2025 and the Form 4 was signed/filed on 08/20/2025 by an attorney-in-fact.

What is the reporting person's relationship to ZVRA?

John B. Bode is a director of Zevra Therapeutics, Inc., as indicated on the Form 4.

Did the Form 4 report any derivative or option transactions for ZVRA?

No. Table II for derivative securities contains no reported transactions; only a non-derivative purchase is recorded.

How many shares does the reporting person own after the reported transaction?

45,000 shares beneficially owned following the 5,000-share purchase.